Researchers at ETH Zurich have refined the famous CRISPR-Cas method. Now, for the very first time, it is possible to modify dozens, if not hundreds, of genes in a cell simultaneously.
Everyone’s talking about CRISPR-Cas. This biotechnological method offers a relatively quick and easy way to manipulate single genes in cells, meaning they can be precisely deleted, replaced or modified. Furthermore, in recent years, researchers have also been using technologies based on CRISPR-Cas to systematically increase or decrease the activity of individual genes. The corresponding methods have become the worldwide standard within a very short time, both in basic biological research and in applied fields such as plant breeding.
To date, for the most part, researchers could modify only one gene at a time using the method. On occasion, they managed two or three in one go; in one particular case, they were able to edit seven genes simultaneously. Now, Professor Randall Platt and his team at the Department of Biosystems Science and Engineering at ETH Zurich in Basel have developed a process that – as they demonstrated in experiments – can modify 25 target sites within genes in a cell at once. As if that were not enough, this number can be increased still further, to dozens or even hundreds of genes, as Platt points out. At any rate, the method offers enormous potential for biomedical research and biotechnology. “Thanks to this new tool, we and other scientists can now achieve what we could only dream of doing in the past.”
Targeted, large-scale cell reprogramming
Genes and proteins in cells interact in many different ways. The resulting networks comprising dozens of genes ensure an organism’s cellular diversity. For example, they are responsible for differentiating progenitor cells to neuronal cells and immune cells. “Our method enables us, for the first time, to systematically modify entire gene networks in a single step,” Platt says.
Moreover, it paves the way for complex, large-scale cell programming. It can be used to increase the activity of certain genes, while reducing that of others. The timing of this change in activity can also be precisely controlled.
This is of interest for basic research, for example in investigating why various types of cells behave differently or for the study of complex genetic disorders. It will also prove useful for cell replacement therapy, which involves replacing damaged with healthy cells. In this case, researchers can use the method to convert stem cells into differentiated cells, such as neuronal cells or insulin-producing beta cells, or vice versa, to produce stem cells from differentiated skin cells.
The dual function of the Cas enzyme
The CRISPR-Cas method requires an enzyme known as a Cas and a small RNA molecule. Its sequence of nucleobases serves as an “address label”, directing the enzyme with utmost precision to its designated site of action on the chromosomes. ETH scientists have created a plasmid, or a circular DNA molecule, that stores the blueprint of the Cas enzyme and numerous RNA address molecules, arranged in sequences: in other words, a longer address list. In their experiments, the researchers inserted this plasmid into human cells, thereby demonstrating that several genes can be modified and regulated simultaneously.
For the new technique, the scientists did not use the Cas9 enzyme that has featured in most CRISPR-Cas methods to date, but the related Cas12a enzyme. Not only can it edit genes, it can also cut the long “RNA address list” into individual “address labels” at the same time. Furthermore, Cas12a can handle shorter RNA address molecules than Cas9. “The shorter these addressing sequences are, the more of them we can fit onto a plasmid,” Platt says.
Learn more: Revolutionising the CRISPR method
The Latest on: CRISPR
via Google News
The Latest on: CRISPR
- Mitigation of off-target toxicity in CRISPR-Cas9 screens for essential non-coding elementson September 6, 2019 at 2:22 am
Pooled CRISPR-Cas9 screens are a powerful method for functionally characterizing regulatory elements in the non-coding genome, but off-target effects in these experiments have not been systematically ...
- CRISPR-Cas9-based mutagenesis frequently provokes on-target mRNA misregulationon September 6, 2019 at 2:13 am
The introduction of insertion-deletions (INDELs) by non-homologous end-joining (NHEJ) pathway underlies the mechanistic basis of CRISPR-Cas9-directed genome editing. Selective gene ablation using ...
- Cellular Computers Get a Boost With CRISPRon September 4, 2019 at 7:27 am
Cancer’s impenetrable secrets partly rely on its mysterious molecular history. As cells turn to the dark side, a whirlwind of DNA changes gradually accumulate. Like flipping multiple interlinked light ...
- A CRISPR Doyen Discusses Gene-Editing Challengeson September 4, 2019 at 5:32 am
Jennifer Doudna, winner of the 2018 Kavli Prize in Nanoscience, talks to Scientific American about what it’s like to work in perhaps the hottest research area in all of biology. She also discusses the ...
- Novel CRISPR method identifies key genes for Toxoplasma survivalon September 3, 2019 at 6:22 am
Using a new approach to genetic screening with CRISPR, researchers at the Crick have identified key genes for the survival of the parasite Toxoplasma gondii in mice. CRISPR screening is an ...
- Four U.S. CRISPR Trials Editing Human DNA to Research New Treatmentson September 3, 2019 at 5:06 am
Last fall, the birth of genetically edited twin girls in China—the world’s first “designer babies”—prompted an immediate outcry in the medical science community. The change to the twins’ genomes, ...
- University of California granted new U.S. CRISPR-Cas9 patent related to single-guide RNAon September 2, 2019 at 9:46 pm
University's 12th U.S. patent adds new compositions for CRISPR-Cas9 gene-editing technology to overall patent portfolio; expects to add five more patents in near future BERKELEY, Calif., Sept.
- CRISPR could lead to gene-editing fix for a form of male infertilityon September 1, 2019 at 4:55 am
Male mice with a mutation that prevented them producing any sperm have fathered offspring the natural way after a team in China fixed their infertility by CRISPR genome editing. The technique could ...
- Giant virus has evolved its own kind of CRISPR to destroy invaderson September 1, 2019 at 12:22 am
The mimivirus is so enormous it has its own kind of CRISPR-like immune system to defend against the smaller viruses that attack it. A team in France has confirmed how it works by transferring the ...
- BRIEF-Crispr Therapeutics AG May Offer And Sell From Time To Time Its Common Shares Having Aggregate Offering Price Of Up To $200 Millionon August 30, 2019 at 1:39 pm
Aug 30 (Reuters) - CRISPR Therapeutics AG: * CRISPR THERAPEUTICS AG - MAY OFFER AND SELL FROM TIME TO TIME ITS COMMON SHARES HAVING AGGREGATE OFFERING PRICE OF UP TO $200 MILLION * CRISPR THERAPEUTICS ...
via Bing News